---
title: "Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death "
description: "Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death in bladder cancer patients by 50% and decreased the risk of recurrence and metastasis events by 60%"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261731590.md"
published_at: "2025-10-18T14:38:10.000Z"
---

# Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death 

> Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death in bladder cancer patients by 50% and decreased the risk of recurrence and metastasis events by 60%

Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death in bladder cancer patients by 50% and the risk of recurrence and metastasis events by 60%

### Related Stocks

- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 根据最近的 SEC 文件，默克公司的一位内部人士出售了价值 1,827,992 美元的股票 | 2026 年 2 月 6 日下午 4:30（东部标准时间）——约翰内斯·雅各布斯·奥斯图伊岑（Johannes Jacobus Oosthuizen），美国市场总裁，于 2026 年 2 月 6 日出售了 15,000 股默克公司（Merc | [Link](https://longbridge.com/en/news/275175518.md) |
| 大摩表示，默克的产品线进展和业务发展战略仍然是关注的焦点 | 默克的产品线进展和业务发展战略仍然受到关注，摩根士丹利表示 | [Link](https://longbridge.com/en/news/274841608.md) |
| 默克获得 FDA 批准，Keytruda 联合疗法用于治疗卵巢癌 | 默沙东已获得 FDA 批准，将 Keytruda 和 Keytruda Qlex 与紫杉醇联合用于治疗铂耐药性卵巢癌。该批准基于 III 期 KEYNOTE-B96 试验数据，显示 PD-L1 表达肿瘤患者在无进展生存期和总体生存期方面有显 | [Link](https://longbridge.com/en/news/275742611.md) |
| 美国食品药品监督管理局批准默克的 KEYTRUDA 治疗方案用于铂耐药性卵巢癌 | 美国食品药品监督管理局（FDA）已批准默克的 KEYTRUDA 治疗方案，用于治疗 PD-L1 阳性铂耐药性卵巢癌的成人患者。这包括 KEYTRUDA®和 KEYTRUDA QLEX™与紫杉醇联合使用，是否联合贝伐单抗均可，适用于接受过一至 | [Link](https://longbridge.com/en/news/275598070.md) |
| 默克宣布美国食品药品监督管理局批准了 KEYTRUDA（帕博利珠单抗和贝拉透明质酸酶 Alfa-Pmph）以及 KEYTRUDA QLEX | 默克宣布，美国 FDA 已批准 KEYTRUDA（帕博利珠单抗和贝拉肝素酶 alfa-pmph）用于治疗经过一至两次治疗的 PD-L1+ 铂耐药性卵巢癌成人患者。此外，KEYTRUDA 和 KEYTRUDA QLEX 也被批准用于与化疗联合 | [Link](https://longbridge.com/en/news/275617117.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.